News

Metformin linked to lower risk of lung cancer in diabetic nonsmokers


 

References

In nonsmokers with diabetes, patients who used metformin had a decreased risk of lung cancer, according to Dr. Lori Sakoda and associates at the Kaiser Permanente Division of Research, Oakland, Calif.

In a retrospective cohort study of 47,351 diabetic patients, 46% were metformin users. In total, 747 patients were diagnosed with lung cancer during follow-up of 15 years, including 80 nonsmokers and 203 current smokers. Metformin use was associated with a 43% lower lung cancer risk in diabetic nonsmokers, with risk continuing to decrease with longer use of the drug. Metformin use was not associated with lower lung cancer risk overall.

These results suggest that the risks associated with metformin may vary according to a patient’s smoking history, Dr. Sakoda said. Read the full article at: http://cancerpreventionresearch.aacrjournals.org/.

Recommended Reading

Biopsy remains most costly lung cancer diagnosis tool
MDedge Hematology and Oncology
Nivolumab monotherapy reaches advanced squamous NSCLC
MDedge Hematology and Oncology
Carboplatin, etoposide yield similar survival in NSCLC
MDedge Hematology and Oncology
Proposed criteria for lung cancer screening with LDCT may not be most efficient
MDedge Hematology and Oncology
First-line crizotinib superior for ALK-positive NSCLC
MDedge Hematology and Oncology
Hookah, snus users more likely to start smoking
MDedge Hematology and Oncology
Cancer patients with incidental VTE have high risk of recurrent thrombi
MDedge Hematology and Oncology
Ramucirumab approved for metastatic NSCLC
MDedge Hematology and Oncology
ASCO, AACR recommend against using e-cigarettes as first line for smoking cessation for cancer patients
MDedge Hematology and Oncology
Adding cisplatin to docetaxel monotherapy provides no benefit for elderly with NSCLC
MDedge Hematology and Oncology